Published in Medical Letter on the CDC and FDA, March 26th, 2006
Priority review designation is granted to drugs that, if approved, would be a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease.
Schering-Plough is seeking U.S. marketing approval of Noxafil for prophylaxis of serious invasive fungal infections, including both moulds and yeasts, in patients who are at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA